Zinc supplementation affects favorably the frequency of migraine attacks: a double-blind randomized placebo-controlled c
- PDF / 533,705 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 21 Downloads / 174 Views
RESEARCH
Open Access
Zinc supplementation affects favorably the frequency of migraine attacks: a doubleblind randomized placebo-controlled clinical trial Hedieh Ahmadi1†, Seyedeh Shabnam Mazloumi-Kiapey2, Omid Sadeghi3,4†, Morteza Nasiri5,6, Fariborz Khorvash7, Tayebeh Mottaghi1 and Gholamreza Askari1*
Abstract Background: Observational studies have shown a link between zinc deficiency and migraine headaches. We aimed to examine the effect of zinc supplementation on the characteristics of migraine attacks in patients with migraine. Methods: This randomized clinical trial was conducted on 80 patients with migraine. Patients were randomly assigned to receive either zinc sulfate (220 mg/d zinc sulfate) or placebo (lactose) for 8 weeks. Anthropometric measures, serum zinc concentrations, and characteristics of migraine attacks (headache severity, frequency and duration of migraine attacks, and headache daily results) were assessed at baseline and end of the trial. Results: Compared with the placebo, zinc supplementation resulted in a significant reduction in headache severity (− 1.75 ± 1.79 vs. -0.80 ± 1.57; P = 0.01) and migraine attacks frequency (− 2.55 ± 4.32 vs. -0.42 ± 4.24; P = 0.02) in migraine patients. However, the observed reduction for headache severity became statistically non-significant when the analysis was adjusted for potential confounders and baseline values of headache severity. Other characteristics of migraine attacks including the duration of attacks and headache daily results were not altered following zinc supplementation either before or after controlling for covariates. Conclusion: Zinc supplementation had a beneficial effect on the frequency of migraine attacks in migraine patients. Additional well-designed clinical trials with a long period of intervention and different dosages of zinc are required. Trial registration code: IRCT20121216011763N23 at www.irct.ir. Keywords: Zinc, Migraine, Headache, Clinical trial
* Correspondence: [email protected] † Hedieh Ahmadi is first author and Omid Sadeghi is co-first author 1 Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, P.O. Box 8174673461, Isfahan, Iran Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
Data Loading...
